## CNS Agents - Movement Disorders

[Criteria Document](https://mygainwell-my.sharepoint.com/:w:/g/personal/kaelyn_dobbins_gainwelltechnologies_com/ESsLCjnRyK1CpW82mdhBIYYBuDqngIVzUUBT9yzWgNt4jA?e=zGr9YZ){:target="_blank" rel="noopener}

|||
| ---------- | --------------------------------------- |
| Criteria 1 | Austedo (P, PA, ST)                     |
| Criteria 2 | Ingrezza (P, PA), Tetrabenazine (P, PA) |

 

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong></th>
<th>Central Nervous System (CNS) Agents: Movement Disorders</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong></td>
<td>Austedo</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong></td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products</strong></p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td></td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name</td>
<td>Corresponding Code (s)</td>
<td>Type of Code (GCNSeqNo, HICL, NDC)</td>
</tr>
<tr class="even">
<td></td>
<td>AUSTEDO</td>
<td>077269</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>AUSTEDO</td>
<td>077270</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>AUSTEDO</td>
<td>077271</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number</strong>  </th>
<th><strong>Question ID</strong>  </th>
<th><strong>Default Next Question ID</strong>  </th>
<th><strong>Question Type</strong>  </th>
<th><strong>Question Text</strong>  </th>
<th><strong>Choice Text</strong>  </th>
<th><strong>Next Question ID</strong>  </th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1</td>
<td>1000</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>1001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2 </td>
<td>1001  </td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td><p>3 </p>
<p> </p></td>
<td>1002  </td>
<td></td>
<td>Select  </td>
<td>Is the medication being prescribed by or in consultation with a neurologist or a psychiatrist? </td>
<td>Y </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>4</td>
<td>1003 </td>
<td>  </td>
<td>Select  </td>
<td>What is the patient’s diagnosis? </td>
<td>Tardive Dyskinesia  </td>
<td>END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Huntington’s Disease </td>
<td>1004 </td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other </td>
<td>1235 </td>
</tr>
<tr class="even">
<td>5</td>
<td>1004 </td>
<td> </td>
<td>Select and Free Text   </td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">90 days</span> to a maximally tolerated dose of tetrabenazine?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y  </td>
<td>END (Pending Manual Review)  </td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1235 </td>
</tr>
<tr class="even">
<td>6</td>
<td>1234</td>
<td></td>
<td><p>Select and Free Text </p>
<p>   </p></td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td>Y  </td>
<td>END (Pending Manual Review) </td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1235</td>
</tr>
<tr class="even">
<td>7</td>
<td>1235  </td>
<td>  </td>
<td>Free Text  </td>
<td>Please provide the rationale for the medication being requested.   </td>
<td>END (Pending Manual Review) </td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 days  

| **Last Approved ** | 4/18/2023 |
| ------------------ | --------- |
| **Other**          |           |

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong></th>
<th>Central Nervous System (CNS) Agents: Movement Disorders</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong></td>
<td>Ingrezza, Tetrabenazine</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong></td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products</strong></p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td></td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name</td>
<td>Corresponding Code (s)</td>
<td>Type of Code (GCNSeqNo, HICL, NDC)</td>
</tr>
<tr class="even">
<td></td>
<td>INGREZZA</td>
<td>077294</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>INGREZZA</td>
<td>077791</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>INGREZZA</td>
<td>079676</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>INGREZZA</td>
<td>082227</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>TETRABENAZINE</td>
<td>017750</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>TETRABENAZINE</td>
<td>064582</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number</strong>  </th>
<th><strong>Question ID</strong>  </th>
<th><strong>Default Next Question ID</strong>  </th>
<th><strong>Question Type</strong>  </th>
<th><strong>Question Text</strong>  </th>
<th><strong>Choice Text</strong>  </th>
<th><strong>Next Question ID</strong>  </th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1</td>
<td>1000</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>1001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2 </td>
<td>1001  </td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling? </td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td><p>3 </p>
<p> </p></td>
<td>1002  </td>
<td></td>
<td>Select  </td>
<td>Is the medication being prescribed by or in consultation with a neurologist or a psychiatrist? </td>
<td>Y </td>
<td>END (Approve x 365 days) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>4</td>
<td>1234</td>
<td></td>
<td><p>Select and Free Text </p>
<p>   </p></td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td>Y  </td>
<td>END (Approve x 365 days) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1235  </td>
<td>  </td>
<td>Free Text  </td>
<td>Please provide the rationale for the medication being requested.   </td>
<td>END (Pending Manual Review) </td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 days 

| **Last Approved ** | 4/18/2023 |
| ------------------ | --------- |
| **Other**          |           |
